Dispersive solid-phase extraction based on the combination of biological metal-organic frameworks and covalent organic frameworks for the extraction of imatinib from plasma samples and its determination by high-performance liquid chromatography with mass spectrometry.

Abstract

Imatinib is an oral tyrosine kinase inhibitor is used in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Measuring the concentration of this drug in plasma samples is of great importance for pharmacodynamic, pharmacokinetic studies, and therapeutic evaluations.Purpose:The purpose of this study is to develop a dispersive solid-phase extraction method based on a new nanocomposite to extract imatinib in plasma samples before high-performance liquid chromatography tandem mass spectrometry. In this method, the nanoparticles was prepared by combination of metal-organic frameworks and covalent organic frameworks and used for drug extraction. The adsorbent used has high efficiency in drug extraction due to its high porosity and large surface area. Additionally, due to the biological nature of the adsorbent, it exhibits high biocompatibility.Methods:For this purpose, the nanocomposite was synthesized using the hydrothermal method. After that, particles are contacted with a sample solution containing the analyte, and ultrasonic waves are used to increase the surface contact. After separating the adsorbent particles through centrifugation, the supernatant was discarded, and the analyte adsorbed on the surface of the adsorbent was eluted with 100 microliters of ethanol under vortexing for 3 minutes and then used for analysis by an analytical instrument.Results: The method yielded satisfactory results, including acceptable extraction recovery (59±3), low limits of detection and quantification, acceptable relative standard deviations (≤ 6.58%), and a wide linear range. Finally, the proposed method was employed as a sensitive technique for plasma samples.Conclusions:The results obtained from this method confirm its applicability for the analysis of imatinib in plasma samples. The method demonstrates suitable sensitivity and accuracy, reproducibility of results, minimal matrix effects, and a wide linear range as its advantages. Additionally, effective sample cleanup and the lack of need for complex facilities are other features of this method.